CVS Health January, 2020
Troy Brennan, M.D., Sree Chaguturu, M.D., Daniel Knecht, M.D.

Introduction

After many years of scientific promise but few real results, gene therapies are now a reality. These exciting new interventions have the potential to relieve tremendous suffering for patients with genetic disorders. Making sure these treatments are accessible for all those who need them requires innovative partnerships, as well as new ways of providing health insurance and pharmacy benefit design.

Generally speaking, gene therapies use a target gene that expresses protein products at a sufficient level to cure, or at least ameliorate, a disease caused by a genetic defect. So far, the U.S. Food and Drug Administration (FDA) has approved a handful of gene therapies to treat serious diseases that were previously untreatable except through supportive measures. The European...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Patient / Consumer, Payer, Precision Medicine, Provider, Retail care, Technology
Moderna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.
Report: Prices for top Medicare Part D drugs nearly doubled since entering the market
High cost of weight loss drugs drives employers to require nutrition counseling, in boost for startups
Announcement: Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Fund
Boosting biopharma R&D performance with a next-generation technology stack

Share This Article